[Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].
Monitoring various parameters of fibrinolytic activity in 6 patients with arterial occlusive disease during intra-arterial (i.a.) or intravenous (i.v.) prostaglandin (PG) E1 infusions indicated activation of the endogenous fibrinolytic system. However, due to the small number of patients not all test parameters revealed significant changes. None of the PGE1 infusion regimens used (1.25 or 2.5 ng/kg/min i.a. or 5 or 10 ng/kg/min i.v. for 120 min in each case) led to any significant change in various parameters checked for ex-vivo platelet function. In agreement with these data the radioimmunological determination of PGE1 in venous plasma did not reveal any significant rise. On the other hand, the circulating metabolite of PGE1, 15-keto-13, 14-dihydro-PGE1, reached plasma levels which correlated well with expected theoretical values taking the infusion rate into consideration. A potential mechanism by which even low plasma concentrations of PGE1 might affect platelet function in vivo is discussed.
Fitscha
P
P
Medizinische Abteilung Allgemeine Poliklinik Wien.
Simmet
T
T
Peskar
B A
BA
Reuter
H
H
Sinzinger
H
H
Rogatti
W
W
Tilsner
V
V
D000527:Alprostadil / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D010974:Platelet Aggregation / Q000187:drug effects*
D000527:Alprostadil
Untersuchungen zur fibrinolytischen Aktivität, Thrombozytenfunktion und Pharmakokinetik während intraarterieller oder intravenöser Prostaglandin-E 1-Infusion bei Patienten mit chronisch arterieller Verschlusskrankheit.